Meridian Bioscience (Nasdaq: VIVO) reported earnings on Jan. 25. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q1), Meridian Bioscience missed on revenues and whiffed on earnings per share.

Compared to the prior-year quarter, revenue grew and earnings per share grew.

Gross margins shrank, operating margins increased, and net margins improved.

Revenue details
Meridian Bioscience booked revenue of $40 million. The nine analysts polled by S&P Capital IQ wanted to see revenue of $43 million. Sales were 8.1% higher than the prior-year quarter's $37 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at $0.17. The 10 earnings estimates compiled by S&P Capital IQ averaged $0.19 per share on the same basis. GAAP EPS of $0.16 for Q1 were 6.7% higher than the prior-year quarter's $0.15 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 61.4%, 290 basis points worse than the prior-year quarter. Operating margin was 25.5%, 20 basis points better than the prior-year quarter. Net margin was 16.3%, 10 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $46 million. On the bottom line, the average EPS estimate is $0.21.

Next year's average estimate for revenue is $184 million. The average EPS estimate is $0.85.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 474 rating the stock outperform, and 11 members rating it underperform. Among 131 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 130 give Meridian Bioscience a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is outperform, with an average price target of $21.11.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Meridian Bioscience. Learn how to maximize your investment income and "Secure Your Future With 11 Rock-Solid Dividend Stocks." Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.